Loading
CapsoVision, Inc Stock: price and insider trades · United States
2 insiders bought €17.7M of shares over the last 90 days, the latest filed 23 Sept 2026.
Cluster: 2 buyers in 30 daysCapsoVision, Inc: what insiders have been doing
CapsoVision, Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for CapsoVision, Inc logged 21 filings by 8 insiders.
The flow runs one way only: 3 insiders bought (7 purchases totalling €13.9M) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 2 major shareholders and 1 senior executive among the declarants. One trade stands out by size: a purchase of €4.4M from Harari Eliyahou Et al, disclosed on 23 September 2026, or 1.4% of market capitalisation.
For context, the typical company on the same exchange (median of 5,810 companies) published 19 filings over the same period, against 21 filings here. Our records for CapsoVision, Inc go back to 2025, with 7 purchases and no sales on the open market in total.
In all, 2 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 23 September 2026, 25 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
30
Thresholds
n/a
Buy Volume
€14M
7 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleEliyahou Et al Harari5 buys
Ching Hang Shen2 buys
Chen Lung Tsai1 buy
Since the insiders bought
- -3.9%Entry US$6.91 · Close 14 Oct 2026 US$6.64
- +31.0%Entry US$5.07 · Close 14 Oct 2026 US$6.64
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate CapsoVision, Inc Strong Buy (bullish), based on 2 analysts. Average price target: US$9.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$6.78
Analyst consensus
2 analystsStrong buy
US$9.00Target US$9.50(+40%)US$10.00
Income statement
RevenueUS$13.6M
Gross profitUS$7.2M53% margin
EBITDA-US$24.9M-184% margin
Net income-US$25.3M-214.7% margin
Valuation
P/Book25.8x
Balance sheet & cash
Market capUS$360.8M
Total debtUS$887k
Free Cash Flow-US$23M
Debt / Equity5%
Profitability & ownership
ROE-335.1%
ROA-132.5%
% insiders30.1%
% institutions9.7%
Last declaration on 23 September 2026
Declarations30 total
3,991,606 shares0Common stockSEC:0002102304-26-000005:0
3,991,606 shares0Common stockSEC:0002102304-26-000005:1
878,735 shares@ US$5.691.40% mcap45.4% of flowCommon StockSEC:0001009165-26-000009:0
Canonical exit: 17 Dec 2026 (T+90)
878,734 shares@ US$5.691.40% mcap45.4% of flowCommon StockSEC:0001009165-26-000009:1
Canonical exit: 17 Dec 2026 (T+90)
878,734 shares@ US$5.691.39% mcap100.0% of flowCommon stockSEC:0002102304-26-000003:0
Canonical exit: 14 Dec 2026 (T+90)
61,068 shares@ US$6.730.12% mcap3.7% of flowCommon StockSEC:0001009165-26-000006:0
Canonical exit: 15 Oct 2026 (T+90)
81,300 shares@ US$6.090.14% mcap4.5% of flowCommon StockSEC:0001009165-26-000005:0
Canonical exit: 6 Oct 2026 (T+90)
13,850 shares@ US$7.3510.028% mcap0.9% of flowCommon StockSEC:0001009165-26-000004:0
Canonical exit: 24 Sept 2026 (T+90)
2,022 sharesCommon StockSEC:0001235498-26-000005:0
2,022 sharesCommon StockSEC:0001307275-26-000007:0
2,022 sharesCommon StockSEC:0002074161-26-000005:0
2,022 sharesCommon StockSEC:0002074258-26-000005:0
2,022 sharesCommon StockSEC:0002074262-26-000005:0
2,022 sharesCommon StockSEC:0002075511-26-000008:0
20 shares@ US$4.170.0000% mcap0.3% of flowCommon StockSEC:0001307275-26-000002:0
Canonical exit: 1 Oct 2025 (T+90)
2,887 shares@ US$10.69100.0% of flowCommon StockSEC:0002075511-25-000005:0
2,887 shares@ US$10.6999.7% of flowCommon StockSEC:0001307275-25-000009:0
2,887 shares@ US$10.69100.0% of flowCommon StockSEC:0001235498-25-000007:0
2,887 shares@ US$10.69100.0% of flowCommon StockSEC:0002074262-25-000005:0
2,887 shares@ US$10.69100.0% of flowCommon StockSEC:0002074258-25-000005:0
2,887 shares@ US$10.69100.0% of flowCommon StockSEC:0002074161-25-000005:0
24,834 shares@ US$0.3663100.0% of flowCommon StockSEC:0001378325-25-000014:0
3,186,904 sharesCommon StockSEC:0001009165-25-000004:0
517,759 sharesCommon StockSEC:0001009165-25-000004:1
517,759 sharesCommon StockSEC:0001009165-25-000004:2
25 of 30 declarations
About CapsoVision, Inc
CapsoVision, Inc. is a U.S.-based medical technology company listed on the NASDAQ Capital Market under the ticker CV. Headquartered in Saratoga, California, United States, the company was founded in 2005 and has built its business around advanced imaging and AI-enabled solutions for gastrointestinal diagnostics. Its strategy is centered on capsule endoscopy, combining a wire-free device platform, cloud-based review workflows and internally developed software capabilities.
The company’s lead product is CapsoCam Plus®, a panoramic 360-degree capsule endoscope designed to visualize the small bowel and help clinicians detect conditions such as obscure GI bleeding, anemia and Crohn’s disease. CapsoVision sells the product directly in the U.S. and through direct and indirect channels internationally. Beyond the commercial small-bowel franchise, the company is advancing CapsoCam Colon, a next-generation product intended to enable non-invasive colon visualization and polyp detection. It is also developing an AI-assisted reading module aimed at improving lesion detection sensitivity, shortening review times and enhancing polyp sizing capabilities.
Read moreShow less
From a competitive standpoint, CapsoVision differentiates itself through a wire-free design, proprietary cloud architecture and a growing AI layer. That combination is meant to reduce the need for on-site servers or specialized infrastructure, simplify deployment across care settings and improve physician workflow. In practical terms, the company is targeting gastroenterology practices, hospitals and larger care networks, while also pursuing opportunities in pediatrics and broader screening use cases across the GI tract. Its positioning places it among innovative niche players in capsule endoscopy rather than broad-based medtech platforms.
Recent company updates indicate that CapsoVision is still in a build-and-scale phase, but with meaningful commercial traction. Management reported that CapsoCam Plus had been used in over 161,000 patients as of December 31, 2025. For full-year 2025, revenue increased and the company submitted a 510(k) application to the FDA for its in-house AI-assisted module. In March 2026, CapsoVision also announced the closing of a $14 million private placement, underscoring continued capital needs as it funds product development, regulatory work and commercial expansion. For investors following U.S. listed healthcare names, CV offers exposure to a specialized medtech story on the NASDAQ in the United States, with upside tied to clinical adoption, regulatory approvals and execution in a competitive but structurally attractive GI diagnostics market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
